Circulating endothelial progenitor cells in metronomic chemotherapy using irinotecan and/or bevacizumab for colon carcinoma: study of their clinical significance

Murakami,Hidetsugu; Ogata,Yutaka; Akagi,Yoshito; Ishibashi,Nobuya; Shirouzu,Kazuo

doi:10.3892/etm.2011.253

Circulating endothelial progenitor cells in metronomic chemotherapy using irinotecan and/or bevacizumab for colon carcinoma: study of their clinical significance

Authors:
- Hidetsugu Murakami
- Yutaka Ogata
- Yoshito Akagi
- Nobuya Ishibashi
- Kazuo Shirouzu
View Affiliations

Affiliations: Department of Surgery, Kurume University School of Medicine, Kurume, Japan, Department of Surgery, Kurume University Medical Center, Kurume 839-0863, Japan
Published online on: April 8, 2011 https://doi.org/10.3892/etm.2011.253
Pages: 595-600

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to clarify the antitumor efficacy of metronomic chemotherapy using irinotecan (CPT-11) combined with or without bevacizumab against colon cancer, and the significance of circulating endothelial cell (CECs) and endothelial progenitor cells (CEPs) as a surrogate marker for metronomic chemotherapy. KM12SM cells were implanted into the subcutis of nude mouse. After confirming that the implanted tumors had grown 5 mm in size, group A received an intraperitoneal injection of 40 mg/kg CPT-11 every two weeks for 4 weeks [conventional maximum-tolerated dose (MTD)], group B received 10 mg/kg twice weekly (metronomic), group C received 10 mg/kg twice weekly combined with 5 mg/kg bevacizumab twice weekly (metronomic + anti-angiogenic), and the control group received 0.2 ml of PBS every week. Serial changes of CECs and CEPs in peripheral blood and microvessel density (MVD) in the tumor tissues were evaluated. The results showed that the antitumor activity in group B and in group C was significantly higher than that in group A. A significant inhibition in CEPs on day 15 in the metronomic therapy groups B and C was noted when compared to that in the control group, while there was no significant difference in CECs and CEPs between the groups on days 4 and 8. The MVD on day 15 in metronomic groups was significantly lower than that in group A. In conclusion, metronomic chemotherapy of CPT-11 with or without bevacizumab for colon cancer was more effective than the MTD therapy via anti-angiogenic effects. Sequential measurement of CEPs may be a predictive factor for the efficacy and a decisive factor for the optimal dose of metronomic therapy in colon cancer.

View Figures

View References

1.	Eskens FA: Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer. 90:1–7. 2004. View Article : Google Scholar : PubMed/NCBI
2.	Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
3.	Warren RS, Yuan H, Matli MR, et al: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest. 95:1789–1797. 1995. View Article : Google Scholar
4.	Takahashi Y, Ellis LM and Mai M: The angiogenic switch of human colon cancer occurs simultaneous to initiation of invasion. Oncol Rep. 10:9–13. 2003.PubMed/NCBI
5.	Asahara T, Murohara T, Sullivan A, et al: Isolation of putative progenitor endothelial cells for angiogenesis. Science. 275:964–967. 1997. View Article : Google Scholar : PubMed/NCBI
6.	Asahara T, Takahashi T, Masuda H, et al: VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 18:3964–3972. 1999. View Article : Google Scholar : PubMed/NCBI
7.	Bocci G, Francia G, Man S, et al: Thrombospondin 1, a mediator of the anti-angiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA. 100:12917–12922. 2003. View Article : Google Scholar : PubMed/NCBI
8.	Kerbel RS and Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 4:423–436. 2004. View Article : Google Scholar : PubMed/NCBI
9.	Monestiroli S, Mancuso P, Burlini A, et al: Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res. 61:4341–4344. 2001.PubMed/NCBI
10.	Bocci G, Nicolaou KC and Kerbel RS: Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective anti-angiogenic window for various chemotherapeutic drugs. Cancer Res. 62:6938–6943. 2002.PubMed/NCBI
11.	Shaked Y, Emmenegger U, Man S, et al: Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum anti-angiogenic activity. Blood. 106:3058–3061. 2005. View Article : Google Scholar : PubMed/NCBI
12.	Shimada Y, Yoshino M, Wakui A, et al: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study group. J Clin Oncol. 11:909–913. 1993.PubMed/NCBI
13.	Rothenberg ML, Cox JV, deVore RF, et al: A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer. 85:786–795. 1999. View Article : Google Scholar : PubMed/NCBI
14.	Kim KJ, Li B, Winer J, et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature. 362:841–844. 1993. View Article : Google Scholar : PubMed/NCBI
15.	Gerber HP and Ferrara N: Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65:671–680. 2005.PubMed/NCBI
16.	Beaudry P, Force J, Naumov G, et al: Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of anti-angiogenic activity. Clin Cancer Res. 11:3514–3522. 2005. View Article : Google Scholar
17.	Nitta K, Yokokura T, Sawada S, et al: Antitumor activity of novel derivatives of camptothecin. Jpn J Cancer Chemother. 14:850–857. 1987.
18.	Bertolini F, Paul S, Mancuso P, et al: Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 63:4342–4346. 2003.
19.	Capillo M, Mancuso P, Gobbi A, et al: Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res. 9:377–382. 2003.PubMed/NCBI
20.	Mizobe T, Ogata Y, Murakami H, et al: Efficacy of the combined use of bevacizumab and irinotecan as a postoperative adjuvant chemotherapy in colon carcinoma. Oncol Rep. 20:517–523. 2008.PubMed/NCBI
21.	Klement G, Baruchel S, Rak J, et al: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 105:R15–R24. 2000. View Article : Google Scholar : PubMed/NCBI
22.	Browder T, Butterfield CE, Kraling BM, et al: Anti-angiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60:1878–1886. 2000.PubMed/NCBI
23.	Colleoni M, Rocca A, Sandri MT, et al: Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 13:73–80. 2002. View Article : Google Scholar : PubMed/NCBI
24.	De Bont ES, Guikema JE, Scherpen F, et al: Mobilized human CD34⁺ hematopoietic stem cells enhance tumor growth in a nonobese diabetic/severe combined immunodeficient mouse model of human non-Hodgkin’s lymphoma. Cancer Res. 61:7654–7659. 2001.
25.	Schuch G, Heymach JV, Nomi M, et al: Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res. 63:8345–8350. 2003.PubMed/NCBI
26.	Twelves C; Xeloda Colorectal Cancer group: Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur J Cancer. 38(Suppl. 2): S15–S20. 2002. View Article : Google Scholar : PubMed/NCBI
27.	Douillard JY, Hoff PM, Skillings JR, et al: Multicenter phase III study of uracil/tegafur and peroral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 20:3605–3616. 2002. View Article : Google Scholar
28.	Santini D, Vincenzi B, Schiavon G, et al: Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study. Cancer Chemother Pharmacol. 59:613–620. 2007. View Article : Google Scholar : PubMed/NCBI
29.	Goto A, Yamada Y, Yasui H, et al: Phase II study of combination therapy with S-l and irinotecan in patients with advanced colorectal cancer. Ann Oncol. 6:968–973. 2006. View Article : Google Scholar : PubMed/NCBI
30.	Kato H, Ichinose Y, Ohta M, et al: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 350:1713–1721. 2004. View Article : Google Scholar : PubMed/NCBI
31.	Ogata Y, Sasatomi T, Mori S, et al: Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma. Anticancer Res. 27:2605–2612. 2007.PubMed/NCBI